AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Trial Details

NCT ID

NCT05850234

Phase

PHASE1 / PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Relapsed/Refractory Multiple Myeloma

Interventions

AZD0120

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Phoenix, Arizona, United States|33.44838,-112.07404
La Jolla, California, United States|32.84727,-117.2742
Los Angeles, California, United States|34.05223,-118.24368
San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

≥18 years of age at the time of consent.
ECOG performance status of 0 or 1.
Documented diagnosis of MM per IMWG diagnostic criteria.
Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →